Thursday, October 30, 2025 2:20:47 PM
A question doc, do you think BP believes it will be cheaper to partner with NWBO rather than a B/O? I don't understand how Merck has not bought them out considering they only have keytruda monopoly for 2 more years.
"Keytruda profits for merck this year 2025
Merck's Keytruda has been a significant contributor to the company's profits in 2025. The drug's sales reached $8.14 billion, marking a 10% increase from the previous year. This performance has been attributed to strong demand for Keytruda as a treatment for various cancers. Merck's full-year adjusted earnings for 2025 are expected to range between $8.93 and $8.98 per share, reflecting the company's strategy to offset revenue losses from the upcoming patent expiration of Keytruda in 2028."
When LP talks about a franchise, do you think she means NWBO will be the only company to allow dc-vax/ keytruda combo after 2028? Is LP playing the 2 year long game?
Interesting to see yesterdays dilution being absorbed by the market.
"Keytruda profits for merck this year 2025
Merck's Keytruda has been a significant contributor to the company's profits in 2025. The drug's sales reached $8.14 billion, marking a 10% increase from the previous year. This performance has been attributed to strong demand for Keytruda as a treatment for various cancers. Merck's full-year adjusted earnings for 2025 are expected to range between $8.93 and $8.98 per share, reflecting the company's strategy to offset revenue losses from the upcoming patent expiration of Keytruda in 2028."
When LP talks about a franchise, do you think she means NWBO will be the only company to allow dc-vax/ keytruda combo after 2028? Is LP playing the 2 year long game?
Interesting to see yesterdays dilution being absorbed by the market.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
